血脂康胶囊联合阿托伐他汀钙治疗高血压合并冠心病患者的效果

Effects of Xuezhikang capsules combined with Atorvastatin calcium in treatment of patients with hypertension complicated with coronary heart disease

目的:观察血脂康胶囊联合阿托伐他汀钙治疗高血压合并冠心病患者的效果。方法:选取2020年3月至2023年3月该院收治的85例高血压合并冠心病患者进行前瞻性研究,按照随机数字表法将其分为对照组42例和研究组43例。对照组采用阿托伐他汀钙治疗,研究组在对照组基础上联合血脂康胶囊治疗,比较两组临床疗效,治疗前后脂代谢指标[低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)]、血管内皮功能指标[内皮素-1(ET-1)、一氧化氮(NO)、同型半胱氨酸(Hcy)]和血压水平。结果:研究组治疗总有效率为95.35%(41/43),高于对照组的78.57%(33/42),差异有统计学意义(P<0.05);治疗后,研究组TG、LDL-C水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);治疗后,研究组ET-1、Hcy水平均低于对照组,NO水平高于对照组,差异有统计学意义(P<0.05);治疗后,研究组收缩压、舒张压水平均低于对照组,差异有统计学意义(P<0.05)。结论:血脂康胶囊联合阿托伐他汀钙治疗高血压合并冠心病患者可提高治疗总有效率,改善脂代谢指标和血管内皮功能指标水平,降低血压水平,效果优于单纯阿托伐他汀钙治疗。

Objective:To observe effects of Xuezhikang capsules combined with Atorvastatin calcium in treatment of patients with hypertension complicated with coronary heart disease.Methods:A prospective study was conducted on 85 patients with hypertension and coronary heart disease admitted to this hospital from March 2020 to March 2023.According to the random number table method,they were divided into control group(42 cases)and study group(43 cases).The control group was treated with Atorvastatin calcium,while the study group was treated with Xuezhikang capsules on the basis of that of the control group.The clinical efficacy and the levels of lipid metabolism indexes[low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),triacylglycerol(TG)],vascular endothelial function indexes[endothelin-1(ET-1),nitric oxide(NO),homocysteine(Hcy)]and blood pressure were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 95.35%(41/43),which was higher than 78.57%(33/42)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TG and LDL-C in the study group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of ET-1 and Hcy in the study group were lower than those in the control group,the level of NO was higher than that in the control group,and the differences were statistically significant(P<0.05).Further,after the treatment,the levels of systolic blood pressure and diastolic blood pressure in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:Xuezhikang capsules combined with Atorvastatin calcium in the treatment of the patients with hypertension and coronary heart disease can improve the total effective rate of treatment,improve the levels of lipid metabolism indexes and vascular endothelial function indexes,and reduce the levels of blood pressure.Moreover,it is superior to simple Atorvastatin calcium treatment.